-
03.20.2025 | Spin-off da U.Porto recebe investimento de 2 milhões de dólares
Consórcio de investidores CARB-X vai apoiar a Immunethep no desenvolvimento de uma vacina contra infeções invasivas por E.coli.
-
03.20.2025 | Scout Health pursuing point-of-care, home MDx testing using novel multiplexing chemistry
Scout Health is aiming to expand the use of point-of-care molecular testing — perhaps even to consumers' homes — with a novel approach that enables sensitive and specific single-tube multiplexing of isothermal nucleic acid amplification.
-
03.19.2025 | Biotech updates: A first dosing and a setback
LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, launched the Phase 1 clinical trial (NCT06719219) in the U.S. after receiving a Fast Track designation from the U.S. Food and Drug Administration (FDA) in 2024.
-
03.11.2025 | FILA 2025: Emerging Innovators, Bugworks Research, on why 2025 will be a watershed year
With three clinical trials underway, and preparations to integrate more artificial intelligence and machine learning for drug discovery, the company that works towards innovating a novel class of antibiotics and cancer drugs is ready for a crucial year.
-
03.11.2025 | Bugworks: Innovating a novel class of antibiotics, cancer drugs
The founders of Bugworks Research are attempting to bring to market a new class of antibiotics – a first in almost half a century.
-
03.05.2025 | Centauri Therapeutics selects first clinical candidate for immunotherapy against Gram-negative infections
As antibiotic resistance escalates, the urgency for alternative treatments intensifies. Centauri Therapeutics Limited stands at the forefront of this revolution with its groundbreaking ABX-01 program.
-
03.04.2025 | Centauri therapeutics selects first ABX-01 clinical candidate
Centauri Therapeutics Limited has announced the selection of its first clinical candidate for the ABX-01 programme.
-
03.04.2025 | Raleigh firm launches Kinvard Bio to focus on antimicrobial resistance
Kineticos Life Sciences, a Raleigh investment firm, has formed a startup to develop a new generation of antibiotics that can overcome drug-resistant infections.
-
03.04.2025 | Forbes India Leadership Awards 2025: Honoring excellence and innovation
BugWorks Research was recognized for its exceptional innovation in biotechnology. The company’s leadership team, Dr. Anand Anandkumar, Dr. V. Balasubramanium, and Dr. Santanu Datta, emphasized that true innovation is not just about discovery but about creating tangible impact.
-
03.04.2025 | Seres Therapeutics receives feedback from FDA on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) development approach
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections as of 30 days post HSCT in the next study.
-
02.27.2025 | These portable diagnostics go where labs can’t
Federal funding supports engineer Jeff Wang's work to create affordable devices that expand access to health care, leading to faster diagnosis and better health outcomes.
-
02.25.2025 | CARB-X to fund development of E coli vaccine
CARB-X announced today that it is awarding $2 million to Portuguese biotechnology company Immunethep to develop a vaccine against invasive serotypes of Escherichia coli.
-
02.25.2025 | Harvard startup creating a new class of antibiotics
When penicillin, the first antibiotic approved for widespread use, became available in the 1940s, The New York Times reported it as “the most powerful germ killer ever discovered.”
-
02.24.2025 | Small Harvard start-up launches to fight huge problem of antimicrobial resistance
In the face of growing resistance to common antibiotics the world over, North Carolina biotech Kinvard Bio launched on Monday with a mission to develop next-generation drugs that can combat rising “superbugs.”
-
02.20.2025 | LimmaTech franchit un cap : un vaccin innovant contre Staphylococcus aureus entre en phase clinique
La biotech suisse LimmaTech Biologics franchit une étape majeure dans la lutte contre Staphylococcus aureus (S. aureus) en lançant son premier essai clinique de phase 1 pour son candidat-vaccin LBT-SA7.
-
02.18.2025 | LimmaTech impft erstmals in Phase-1-Studie mit LBT-SA7
LimmaTech Biologics hat in den USA die ersten Teilnehmer einer Phase-1-Studie mit seinem multivalenten Impfstoffkandidaten LBT-SA7 geimpft.
-
02.18.2025 | Investigational Staphylococcus aureus vaccine begins Phase 1 study
Munich, Germany-based LimmaTech Biologics AG, announced yesterday that the first participants of a phase 1 trial have been vaccinated with the company’s multivalent vaccine candidate, LBT-SA7.
-
02.14.2025 | Preventive antimicrobials: A promising solution to antibiotic resistance
The health care industry is at a key juncture in the fight against infections. Antibiotic resistance continues to rise, threatening current medical practice patterns. One potential remedy would benefit patients, providers and payers alike: preventive antimicrobials.
-
02.12.2025 | Rapid diagnostic system to detect neonatal sepsis within hours
Neonatal sepsis is a life-threatening condition caused by bloodstream infections in newborns under 28 days old.
-
02.11.2025 | CARB-X funds rapid test to detect pneumonia from urine samples
CARB-X today announced an award of $1 million to Pearl Diagnostics to develop a low-cost, rapid test to diagnose pneumonia caused by Pseudomonas aeruginosa from urine samples.
-
02.10.2025 | CARB-X awards $3M to AstraDx for neonatal sepsis test development
CARB-X said last week that it is awarding $3 million to diagnostics startup AstraDx to support the development of a rapid test for neonatal sepsis.
-
02.07.2025 | CARB-X funds development of rapid diagnostic test for neonatal sepsis
CARB-X announced yesterday that it is awarding $3 million to diagnostics company AstraDx to develop a rapid diagnostic test for neonatal sepsis.
-
02.07.2025 | Brown University Health pneumonia MDx development offers hint of digital PCR’s potential as IVD tool
A newly funded project at Brown University Health's Rhode Island Hospital aims to create a blood-based pathogen RNA test for pneumonia.
-
02.07.2025 | Brown University Health pneumonia MDx development offers hint of digital PCR’s potential as IVD tool
A newly funded project at Brown University Health's Rhode Island Hospital aims to create a blood-based pathogen RNA test for pneumonia.
-
02.07.2025 | AstraDx receives $3M CARB-X funding for neonatal sepsis test
CARB-X has awarded $3 million to diagnostics company AstraDx to develop a rapid test for neonatal sepsis.
-
02.07.2025 | CARB-X funds development of rapid diagnostic test for neonatal sepsis
CARB-X announced yesterday that it is awarding $3 million to diagnostics company AstraDx to develop a rapid diagnostic test for neonatal sepsis.
-
02.03.2025 | Rhode Island Hospital advances pneumonia diagnosis with rapid blood test study
When it comes to pneumonia, it could take a few days to figure out if it's viral or bacterial to best determine how to treat it. New research promises to change that.
-
01.31.2025 | Novel test to diagnose bacterial pneumonia directly from whole blood
One of the major challenges in diagnosing pneumonia is the difficulty in obtaining an appropriate sample, and frequently, no pathogen is identified.
-
01.30.2025 | Nowe finansowanie dla terapii CMTX-101 – nadzieja na skuteczniejsze leczenie infekcji płuc w mukowiscydozie
Firma Clarametyx Biosciences, specjalizująca się w innowacyjnych terapiach przeciwbakteryjnych, otrzymała wsparcie finansowe od funduszu Kineticos AMR Accelerator Fund (KAMRA Fund).
-
01.30.2025 | Clarametyx Biosciences receives investment from Kineticos AMR Accelerator Fund
Clarametyx Biosciences, a Columbus, OH-based clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, received an investment from Kinetics AMR Accelerator Fund.
-
01.30.2025 | Investment to support CMTX-101 testing for chronic lung infections
Clarametyx Biosciences has announced an investment from Kineticos AMR Accelerator Fund to support the development of CMTX-101, a non-antibiotic treatment candidate for persistent bacterial lung infections in people with cystic fibrosis.
-
01.29.2025 | Neues Antibiotikum wird in Gießen entwickelt
Die Naturstoff-Forschungsgruppe der Justus-Liebig-Universität Gießen erhält rund 950 000 Euro von der Initiative CARB-X.
-
01.29.2025 | Gießen im Kampf gegen Resistenzen: Neues Antibiotikum in Entwicklung!
Die Naturstoff-Forschungsgruppe der Justus-Liebig-Universität Gießen erhält rund 950.000 Euro von der Initiative CARB-X zur Entwicklung eines neuartigen Antibiotikums.
-
01.28.2025 | CARB-X funds Rhode Island Hospital to assess feasibility of direct from blood detection of bacterial pneumonia
CARB-X will award Rhode Island Hospital at Brown University Health US$1M to demonstrate proof-of-concept of a polymerase chain reaction (PCR) approach informed by RNA sequencing to detect bacterial pneumonia directly from whole blood.
-
01.28.2025 | Rhode Island Hospital wins $1M from CARB-X for molecular pneumonia blood test
CARB-X announced Tuesday that it has awarded $1 million to Rhode Island Hospital at Brown University Health to support proof-of-concept studies of a direct-from-blood PCR test informed by RNA sequencing to detect pneumonia-causing bacteria.
-
01.28.2025 | Rhode Island Hospital wins $1M from CARB-X for molecular pneumonia blood test
CARB-X announced Tuesday that it has awarded $1 million to Rhode Island Hospital at Brown University Health to support proof-of-concept studies of a direct-from-blood PCR test informed by RNA sequencing to detect pneumonia-causing bacteria.
-
01.28.2025 | CARB-X funds development of novel pneumonia diagnostic
CARB-X announced today that it is awarding $1 million to Rhode Island Hospital at Brown University Health to develop a test to diagnose bacterial pneumonia from whole blood.
-
01.23.2025 | Vedanta Biosciences publishes additional phase 2 VE303 results in Nature Medicine
BIOSPACE | VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms. Analyses identified predictors of VE303 colonization and protection from CDI recurrence. Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026.
-
01.23.2025 | CARB-X funds development of monoclonal antibody for Staph aureus
CIDRAP | CARB-X announced today that it is awarding $729,000 to Chicago-based biotechnology company Immunartes to develop a monoclonal antibody designed to prevent Staphylococcus aureus infections.
-
01.23.2025 | Debiopharm et GARDP signent un accord pour lutter contre l’antibiorésistance
LE TEMPS | L’entreprise pharmaceutique vaudoise et l’organisation basée à Genève ont annoncé un partenariat pour soutenir le développement d’un nouvel antibiotique contre la gonorrhée.
-
01.21.2025 | Mehr Geld für Antibiotikaforschung in Gießen
AERZTEBLATT | Die Justus-Liebig-Universität Gießen (JLU) erhält von der Initiative CARB-X rund 950.000 Euro in der ersten Förderrunde für die Entwicklung von Molekülen zur Hemmung eines spezifischen Proteins gramnegativer Bakterien.
-
01.17.2025 | CARB-X funds peptide antibiotic
CARB-X announced yesterday that it is awarding $610,000 to Justus Liebig University Giessen in Germany to develop a first-in-class peptide antibiotic.
-
01.15.2025 | Visby Medical secures additional $3.9M from CARB-X to fight antibiotic resistance with PCR-based mutation detection at the POC
Visby Medical, a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from CARB-X to accelerate its fight against antibiotic resistance.
-
01.14.2025 | Nationwide Children’s spinoff targeting antibiotic resistance starts developing vaccine
A Nationwide Children's Hospital spinoff is developing a vaccine based on the same biotechnology it's testing as an antibody treatment attacking chronic drug-resistant infections.
-
01.14.2025 | Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea
The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae.
-
01.14.2025 | CARB-X grants Melio $3.5M for neonatal sepsis rest, Visby wins additional $3.9M
CARB-X announced Tuesday that it will fund diagnostics firm Melio $3.5 million to develop a rapid assay for the detection of neonatal sepsis. In a separate announcement on Wednesday, Visby Medical announced that it has received $3.9 million in additional funding from CARB-X to support its point-of-care gonorrhea assay using instrument-free PCR.
-
01.14.2025 | CARB-X funds rapid diagnostic test platform for bloodstream infections
CARB-X today announced an award of $3.5 million to biotechnology company Melio to develop a rapid diagnostic test for bloodstream infections, including neonatal sepsis.
-
01.14.2025 | CARB-X funds Melio to develop rapid diagnostic to detect neonatal sepsis
CARB-X will award biotechnology company Melio US$3.5M to develop and execute a technical feasibility workplan for its culture-free platform designed to identify blood stream infections including neonatal sepsis.
-
01.10.2025 | Peptilogics receives $3.3 million from CARB-X to develop treatment for fracture-related infections
CARB-X yesterday announced an award of $3.3 million to Pittsburgh-based Peptilogics to develop a slow-release version of its investigational, broad-spectrum therapeutic for joint-related infections.
-
01.09.2025 | CARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections
CARB-X will award Peptilogics US$3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.
-
01.09.2025 | Seres Therapeutics announces new translational biomarker results from SER-155 Phase 1b clinical study and provides corporate updates
Seres Therapeutics, a leading live biotherapeutics company, today announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled study in patients undergoing allogenic stem cell transplantation (allo-HSCT).
-
01.08.2025 | Basilea provides portfolio update and outlook
Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress of its Research & Development portfolio in 2024 and upcoming milestones.
Toggle navigation